{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:30:00Z","timestamp":1794479400168,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.healun.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:39:29Z","timestamp":1783957169000},"page":"1871-1876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping the mTOR pathway in lung transplantation: Is it time for a biomarker-driven precision therapy?"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-4683","authenticated-orcid":false,"given":"Francesca","family":"Lunardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4008-4937","authenticated-orcid":false,"given":"Giuseppe","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-0617","authenticated-orcid":false,"given":"Federica","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8369-4145","authenticated-orcid":false,"given":"Lorenzo","family":"Zaffiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-9226","authenticated-orcid":false,"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1749-6632.1993.tb35852.x","article-title":"Rapamycin: in vitro profile of a new immunosuppressive macrolide","volume":"685","author":"Sehgal","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.healun.2026.07.009_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imr.12845","article-title":"mTOR signaling at the crossroads of environmental signals and T-cell fate decisions","volume":"295","author":"Huang","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.healun.2026.07.009_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3406032","article-title":"The regulatory effects of mTOR complexes in the differentiation and function of CD4 + T cell subsets","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.healun.2026.07.009_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cytogfr.2017.04.005","article-title":"Control of B lymphocyte development and functions by the mTOR signaling pathways","volume":"35","author":"Iwata","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.healun.2026.07.009_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01653-16","article-title":"mTOR promotes antiviral humoral immunity by differentially regulating CD4 helper T cell and B cell responses","volume":"91","author":"Ye","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.healun.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.1600-6143.2006.01355.x","article-title":"Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts","volume":"6","author":"Lepin","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.healun.2014.09.047","article-title":"Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts","volume":"34","author":"Li","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib8","article-title":"Phosphorylation of S6RP in peritubular capillaries of kidney grafts and circulating HLA donor-specific antibodies","volume":"9","author":"Ra\u00efch-Regu\u00e9","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.healun.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.healun.2021.06.021","article-title":"Phosphorylated S6 ribosomal protein expression by immunohistochemistry correlates with de novo donor-specific HLA antibodies in lung allograft recipients","volume":"40","author":"Cone","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.healun.2023.10.002","article-title":"Assessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection","volume":"43","author":"Lunardi","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.healun.2026.02.1666","article-title":"Human lung allografts experience persistent fibrogenic shift following acute cellular rejection","volume":"45","author":"Potter","year":"2026","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":"Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial","volume":"16","author":"Strueber","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.12659\/AOT.908471","article-title":"Early sirolimus-based immunosuppression is safe for lung transplantation patients: retrospective, single arm, exploratory study","volume":"23","author":"Wojarski","year":"2018","journal-title":"Ann Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib15","article-title":"Survival associated with sirolimus plus tacrolimus maintenance without induction therapy compared with standard immunosuppression after lung transplant","volume":"2","author":"Wijesinha","year":"2019","journal-title":"JAMA New Open"},{"key":"10.1016\/j.healun.2026.07.009_bib16","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/TP.0000000000004095","article-title":"Five-year outcome of an early everolimus-based quadruple immunosuppression in lung transplant recipients: follow-up of the 4EVERLUNG study","volume":"106","author":"Kneidinger","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2026.07.009_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.10581","article-title":"Rescue everolimus post lung transplantation is not associated with an increased incidence of CLAD or CLAD-related mortality","volume":"36","author":"Ivulich","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/TP.0000000000004336","article-title":"Mammalian target of rapamycin inhibitors and kidney function after thoracic transplantation: a systematic review and recommendations for management of lung transplant recipients","volume":"107","author":"Schmucki","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.transproceed.2023.09.027","article-title":"Sirolimus long-term tolerability and impact on kidney function in lung transplantation: a single-center experience","volume":"55","author":"Feist","year":"2023","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2026.07.009_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284653","article-title":"Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors","volume":"18","author":"Gottlieb","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.healun.2026.07.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113415","article-title":"The favorable impact of everolimus on Chronic lung allograft dysfunction in lung transplant recipients","volume":"143","author":"Landoas","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.healun.2026.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70211","article-title":"Calcineurin inhibitor replacement with mammalian target of rapamycin (mTOR) inhibitor following lung transplantation","volume":"39","author":"Kommaraju","year":"2025","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1523-1755.2005.00731.x","article-title":"Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy","volume":"68","author":"Hartmann","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.healun.2026.07.009_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FTD.0000000000000616","article-title":"Pharmacodynamic monitoring of mTOR inhibitors","volume":"41","author":"Mill\u00e1n","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2026.07.009_bib26","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1074\/jbc.M115.672170","article-title":"Mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 as key signaling intermediates in mesenchymal cell activation","volume":"291","author":"Walker","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.healun.2026.07.009_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1619771","article-title":"Detection of lung allograft injury through a comprehensive multidisciplinary analysis of donor-derived cell-free DNA in plasma and bronchoalveolar lavage: a real-world single center experience","volume":"16","author":"Calabrese","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.healun.2026.07.009_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.healun.2026.07.009_bib29","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1074\/jbc.M113.463679","article-title":"Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation","volume":"288","author":"Li","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.healun.2026.07.009_bib30","article-title":"A critical role for mTORC2 Pathway in lung fibrosis","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.healun.2026.07.009_bib31","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249826019935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249826019935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:57:30Z","timestamp":1794477450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249826019935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1053249826019935"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2026.07.009","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the mTOR pathway in lung transplantation: Is it time for a biomarker-driven precision therapy?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}